Breaking Stories

AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs

AstraZeneca has struck a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *